Study reveals cause for different outcomes for patients that experience early and late relapse of diffuse large B-cell lymphoma

A recent study conducted by TFRI-funded researchers at BC Cancer sheds light on the cause behind the different outcomes of patients with diffuse large B cell lymphoma (DLBCL) who experienced a relapse in their disease. The study confirmed that patients whose cancer relapses shortly after treatment typically have poor responses to additional chemotherapy-based treatment. However, when the relapse occurs more than two years from the time of diagnosis, the outcomes to chemotherapy are significantly better.

Dr. Ly Vu one of 11 cancer researchers to receive funding from a new grant program committed to challenging gender disparities

BC Cancer scientist Dr. Ly Vu is one of 11 recipients of A Grant of Her Own: The Women Scientists Innovation Award for Cancer Research. This new granting program, developed by the V Foundation for Cancer Research, sees $8 million in funding invested in cancer research being led by women scientists. Dr.

New Hire Focus: Dr. Joseph Lau is advancing radiopharmaceutical research

Dr. Joseph Lau is working to develop the next generation of radiopharmaceuticals for both diagnostic and therapeutic purposes. Radiopharmaceuticals are radioactive compounds used in cancer care. From a diagnostic perspective, his work focusses on making these radioactive agents better able to detect and visualize cancers in the body. From a treatment perspective this helps oncologists determine if a cancer is operable, delineates margins for radiation planning or select targeted-therapies based on molecular properties of cancer.

New Hire Focus: Dr. Carol Chen is unravelling the mysteries of high-grade gliomas

Dr. Carol Chen is dedicated to understanding the complexities and finding innovative solutions to high-grade gliomas (HGGs); a particularly aggressive form of brain cancer affecting children and young adults. The new BC Cancer scientist, who joined the Terry Fox Laboratory in 2023, is focused on understanding how mutations in certain proteins, called histones or histone-modifying enzymes, contribute to the development of HGGs.

The Canadian Centre for Applied Research in Cancer Control (ARCC) is inviting you to submit an abstract for cancer care — The deadline is June 6, 2023

ARCC is pleased to announce that its 12th annual conference, ARCC2023, will take place virtually on September 14-15, 2023. The objective of this conference is to bridge a connection between researchers and decision-makers, using health economics, services, policy and ethics research to improve cancer control and the delivery of cancer care.

Back to top